Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The SynchroMed™ II programmable, implantable pump delivers drug to the intrathecal space via an implanted catheter. SynchroMed™ II pumps can be managed using the Control Workflow™ approach, which is designed to help eliminate systemic opioids and provide effective pain relief.
Targeted drug delivery is a safe, proven, and effective way to manage chronic pain with fewer side effects and lower doses than systemic medication.1
Watch the animation to learn more. (2:24)
The drug enters the pump through the reservoir fill port and passes through the reservoir valve and into the SynchroMed™ II pump reservoir. At normal body temperatures, pressurized gas that is stored below the reservoir expands, exerting pressure on the reservoir. The pressure helps advance the drug into the SynchroMed™ II pump tubing.
The peristaltic action of the SynchroMed™ II pump moves the drug from the pump reservoir, through the pump tubing, check valve, catheter access port, and implanted catheter, to the infusion site.
The catheter access port (CAP) allows injection of the drug into the implanted catheter for drug administration and diagnostic purposes. Drug injected into the CAP bypasses the SynchroMed™ II pump mechanism and goes through the catheter port into the implanted catheter to the infusion site.
Discover the benefits of targeted drug delivery. - (04:01)
Learn about trialing and long-term patient management. (8:24) - (08:24)
Why recommend targeted drug delivery? - (06:00)
Targeted Drug Delivery Conversations - (04:00)
*Medtronic data on file
**95% confidence, 50% of the pumps have a flow rate repeatability of +/- 0.27% between suuccessive 1 mL dispensed volumes within a refill cycle MRI Triangle
*** Under specific conditions for 1.5 T and 3.0 T MRI scans. Refer to product labeling.
† Requires interrogation to confirm pump status.
Product Performance Data
See prospective, long-term multi-center registry study data for intrathecal drug delivery systems
Take a look inside the Medtronic SynchroMed™ II Pump
Enhanced design with increased reliablity
SynchroMed™ II Programmable Pump - Introduction and Evidence - (02:29)
SynchroMed™ II Programmable Pump - Motor Shaft Updates - (02:22)
SynchroMed™ II Programmable Pump - Gear Wheel and Feedthrough Updates - (03:06)
SynchroMed™ II Programmable Pump - Battery Coating Updates - (01:53)
SynchroMed™ II is indicated for chronic intrathecal infusion of Infumorph® preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, Prialt® chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, and chronic intrathecal infusion of Lioresal® Intrathecal (baclofen injection) for the management of severe spasticity. Use of drugs outside these approved indications is off-label.
The use of off-label drugs is known to reduce pump reliability over implant life and may result in a return of underlying symptoms, drug withdrawal symptoms, or a clinically significant or fatal drug underdose. Medtronic's latest reliability data can be found in our Product Performance Report, comprised of data from Medtronic's prospective, long-term multi-center registry, at medtronic.com/ppr.
The SynchroMed™ II clinician programmer provides a simple, guided workflow approach to programming SynchroMed™ II intrathecal pumps.
The myPTM™ personal therapy manager works with the SynchroMed™ II pump to help alleviate unpredictable pain.
Efficio™ management software is designed to simplify your pump practice by offering efficient schedule planning, simple drug tracking, historical dosing insights, and on-demand access to reports.
8637-20 (20 mL reservoir)
4 to 7 years
8637-40 (40 mL reservoir)
4 to 7 years
U.S. Clinician Services
Find educational tools and resources at Medtronic Academy. Learn more about the Dr. Lisa Stearns Academy for treating cancer pain.
Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304-1313.